Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli

Daniela Laricchiuta1,2*, Alessandra Musella1,3, Silvia Rossi1,3 and Diego Centonze1,3

1 IRCCS Fondazione Santa Lucia, Rome, Italy
2 Dipartimento di Psicologia, Facoltà di Medicina e Psicologia, Università “Sapienza” di Roma, Rome, Italy
3 Dipartimento di Neuroscienze, Università Tor Vergata, Rome, Italy

*Correspondence:
Daniela Laricchiuta, Dipartimento di Psicologia, Facoltà di Medicina e Psicologia, Università “Sapienza” di Roma, via dei Marsi 78, 00185 Rome, Italy
e-mail: daniela.laricchiuta@uniroma1.it

Rewarding effects have been related to enhanced dopamine (DA) release in corticolimbic and basal ganglia structures. The DAergic and endocannabinoid interaction in the responses to reward is described. This study investigated the link between endocannabinoid and DAergic transmission in the processes that are related to response to two types of reward, palatable food and novelty. Mice treated with drugs acting on endocannabinoid system (ECS) (URB597, AM251) or DAergic system (haloperidol) were submitted to approach-avoidance conflict tasks with palatable food or novelty. In the same mice, the cannabinoid type-1 (CB1)-mediated GABAergic transmission in medium spiny neurons of the dorsomedial striatum was analyzed. The endocannabinoid potentiation by URB597 magnified approach behavior for reward (food and novelty) and in parallel inhibited dorsostriatal GABAergic neurotransmission. The decreased activity of CB1 receptor by AM251 (alone or with URB597) or of DAergic D2 receptor by haloperidol had inhibitory effects toward the reward and did not permit the inhibition of dorsostriatal GABAergic transmission. When haloperidol was coadministered with URB597, a restoration effect on reward and reward-dependent motor activity was observed, only if the reward was the palatable food. In parallel, the coadministration led to restoring inhibition of CB1-mediated GABAergic transmission. Thus, in the presence of simultaneous ECS activation and inhibition of DAergic system the response to reward appears to be a stimulus-dependent manner.

Keywords: conflicting tasks, approach/avoidance motivation, haloperidol, URB597, AM251

INTRODUCTION

Survival strictly depends on the drive with which subjects seek natural reinforcers, such as food, water, sex, and maternal care. Converging electrophysiological, biochemical, and behavioral evidence implicates the endocannabinoid system (ECS) in the neurobiological events that attribute value to various types of reinforcers (Maldonado et al., 2006; Marsicano and Lutz, 2006; Laricchiuta et al., 2012a,b). The ECS mediates the balance between approach and avoidance behaviors toward stimuli in humans (Van Laere et al., 2009) and rodents (Lafenêtre et al., 2009; Laricchiuta et al., 2012a,b), the detailed mechanism of which is unknown.

Most central ECS functions are mediated by cannabinoid type-1 (CB1) receptors (Freund et al., 2003; Piomelli, 2003) that presynaptically inhibit primarily glutamatergic and GABAergic transmission, but also dopaminergic and cholinergic transmission (Matias and Di Marzo, 2007; Kano et al., 2009). Notably, the reward effects of primary reinforcers or environmental stimuli that are associated with food or drug intake have been related to enhanced dopamine (DA) release in corticolimbic and basal ganglia structures (Bassareo et al., 2002; Ito et al., 2002; Lupica and Riegel, 2005). Thus, DA is a neurosignal that has been evolutionarily adjusted to boost the organism toward reinforcer (Alcaro and Panksepp, 2011).

There is increasing evidence that implicates a dynamic DAergic and endocannabinoid interaction in neuronal, endocrine, and metabolic responses to reward (Di Marzo et al., 2004; Fernández-Ruiz et al., 2010). The inhibitory effects of the ECS against DAergic neurons in mesolimbic structures have been hypothesized to attribute the salience to reward. Supporting this model, CB1 antagonists impair the attribution of salience to a stimulus (De Vries et al., 2001; Fattore et al., 2003). Further, the ECS has been implicated in several neuropsychiatric conditions, including DA-related disorders, such as schizophrenia (Emrich et al., 1997), Parkinson disease (Maccarrone et al., 2003), and drug addiction (Maldonado and Rodriguez de Fonseca, 2002). In these pathological conditions, involvement of the ECS likely reflects the activity of reward circuitry, which comprises midbrain DAergic neurons and their target structures (Berke and Hyman, 2000; Everitt and Wolf, 2002).
This study aimed to behaviorally and electrophysiologically examine endocannabinoid and DAergic involvement in processes that are related to seeking two types of reward: palatable food and novelty. The interaction between the ECS and DAergic system in processing salient information is attracting significant interest.

In this study, mice that were treated with drugs that act on the ECS or DAergic system were subjected to approach-avoidance conflict tasks with two rewards (food or novelty). In addition, CB1-mediated GABAergic transmission in medium spiny neurons of the dorsomedial striatum was analyzed. This area is the ideal structure to study the interplay between the ECS or DAergic systems, because it has a high density of CB1 and DAergic receptors (Piomelli, 2003) and is critical in goal-directed behaviors (Koob and Volkow, 2010).

**MATERIALS AND METHODS**

**SUBJECTS**

Young (32 ± 2 days) male C57BL/6JolaHsd mice (Harlan, Italy) were used. All animals were housed, 4 per cage, with food (Mucedola 4RF21, Italy) and water ad libitum. The mice were kept under a 12-h light/dark cycle with the lights coming on at 07:00 h, controlled temperature (22–23°C), and constant humidity (60 ± 5%). All efforts were made to minimize animal suffering and reduce the number of animals that were used, per the European Directive (2010/63/EU).

All animals (n = 10/group) included in the present study were behaviorally tested in the Approach/Avoidance Y-Maze (A/A Y-Maze) and the Open-Field test with novel object. Both tasks permit to detect crucial components of animal behavior linked to approach-avoidance motivation, as the tendency to explore, encourage exploration of the maze without the presence of food. Because the appetites for palatable foods must be learned (Lafenêtre et al., 2009), 1 week before the behavioral testing, the animals were exposed to a novel palatable food (Fonzies, KP Snack Foods, Munchen, Germany) in their home cages for three consecutive days (Bassareo et al., 2002). Fonzies (8% protein, 33% fat, and 53% carbohydrate, for a caloric value of 541 kcal/100 gm) consist of corn flour, hydrogenate vegetable fat, cheese powder, and salt.

At the start of behavioral testing, the mice were subjected to a 1-day habituation phase in which all Y-Maze arms were opened to encourage exploration of the maze without the presence of food. The white and lit arm was placed on the right side of the apparatus for the first 5 min and then on the left side for the subsequent 5 min. To increase the motivation to search for the reward, the animals were slightly food-deprived by limiting access to food in the 10 h before the test; this procedure did not result in any body weight loss.

The testing phase (24 h after the habituation phase) comprised two 10-trial sessions. In Session 1 (S1), the animal was placed in the starting arm and could choose to enter one of the two arms, both containing the same standard food reward. After eating, the animal was allowed to stand in its cage for a 1-min intertrial interval. At the end of each trial, the reward was replaced. The spatial position of each arm (black and dark or white and lit) was sequentially exchanged and side-balanced during the entire test to exclude any preference with regard to side.

During Session 2 (S2), starting 24 h after S1, the white arm was rewarded with the highly palatable food (Fonzies), and the black arm was rewarded with the standard food pellet. Forty-eighty hours after S2, the animals were retested (S3) in the A/A Y-Maze per the S2 protocol.

The parameters were: white choices, the frequency of entries into the white arm, to study the approach and avoidance components; entry latency in the arm of choice, to study the locomotor component; and defecation boluses, to evaluate anxiety levels.
**BEHAVIORAL TESTING: OPEN-FIELD (OF) TEST WITH NOVEL OBJECT**

Forty-eighty hours after the end of the A/A Y-Maze task, the OF test was performed. The apparatus, placed in a dimly lit room (red light 40 W) and soundproof cubicle room, consisted of a circular arena (diameter 60 cm) that was delimited by a pale gray wall that was 20 cm high. During Session 1 (S1), a single animal was allowed to explore the empty open field, and its baseline level of activity was measured.

During Session 2 (S2), a new appealing object (a gray plastic cone: height: 10 cm, diameter: 6 cm, with a circular base: diameter: 9.5 cm) was inserted in the anxiogenic central location of the arena. Thus, the response to change exhibited by the animal in S2 is an index of its reaction to conflicting situation.

Sessions lasted 10 min, and the intersession interval was 5 min. The apparatus and object were cleaned thoroughly with 70% ethanol and dried after each session to remove scent cues.

The entire test was recorded on a video camera that was mounted on the ceiling. The video feed was relayed to a monitor and processed through an image analyzer (Ethovision, Noldus, Wageningen, the Netherlands).

The parameters that we considered were: *total distance* (in cm) traveled in the arena and mean *velocity*, to study the explorative and locomotor components; *peripheral distance* (expressed as the percentage of total distance traveled in a 6-cm peripheral annulus), *freezing time* and *defecation boluses*, to evaluate anxiety levels; and *contact times* with the object, to study the approach-avoidance components that were elicited by insertion of the new appealing object in an anxiogenic central location of the wide arena. Contact with the object was considered to take place when the mouse’s snout touched it, or when the animal sniffed the object for at least 1 s.

**ELECTROPHYSIOLOGICAL RECORDINGS**

Mice were killed by cervical dislocation under halothane anesthesia. By using a vibratome, corticostriatal coronal slices (200 µm) were prepared from brain fresh tissue and left recovered for 30 min in an Artificial CSF (ACSF) gassed with 95% O₂ – 5% CO₂. The composition (in mM) of the control ACSF was: NaCl (126), KCl (2.5), MgCl₂ (1.2), NaH₂PO₄ (1.2), CaCl₂ (2.4), Glucose (11), NaHCO₃ (25).

Whole-cell patch clamp recordings from single striatal neurons were made by applying negative pressure. The membrane patch was then ruptured by suction and membrane current and potential monitored by using an Axopatch 1D patch clamp amplifier (Molecular Devices, Foster City, CA, USA). Whole-cell access resistances measured in voltage clamp were in the range of 5–20 MΩ.

Whole-cell patch clamp recordings were made with borosilicate glass pipettes (1.8 mm o.d.; 2–3 MΩ), in voltage clamp mode, at the holding potential (HP) of −80 mV.

To detect spontaneous GABA₅-mediated inhibitory postsynaptic currents (sIPSCs), the intracellular solution comprised (in mM): CaCl₂ (110), K⁺-gluconate (30), ethylene glycol-bis (β-aminoethyl ether)-N,N,N',N'-tetra- acetic acid (EGTA; 1.1), HEPES (10), CaCl₂ (0.1), Mg-ATP (4), and Na-GTP (0.3). MK-801 (30 µM) and CNQX (10 µM) were added to the external solution to block NMDA and non-NMDA glutamate receptors, respectively.

sIPSCs were stored using a P-CLAMP 9 (Molecular Devices, Foster City, CA, USA) and analyzed offline on a personal computer with Mini Analysis 5.1 (Synaptosoft, Leonia, NJ, USA). The offline analysis was performed on sIPSCs that were recorded during fixed times (5–10 samples of 2–3 min each, recorded every 2–3 min). Only cells that had stable frequencies (<20% change in the control samples) were considered.

HU210, used in the slices, was first dissolved in DMSO and then in ACSF to the desired final concentration. DMSO alone was used as the control. The concentrations (in µM) of the various drugs were as follows: CNQX (10), HU210 (1), and MK-801 (30) (Tocris, Bristol, UK).

For the electrophysiological data, “n” refers to the number of cells. One to six neurons per animal were recorded. Electrophysiological measures were obtained by pooling data from at least five animals in each group.

**DRUGS**

All drugs were dissolved in vehicle (VHL) that comprised saline solution with 10% DMSO and 5% Tween 80 and administered at volume of 5 ml/kg of body weight. The animals in the URB group (*n* = 10) were first intraperitoneally (i.p.) injected with the fatty acid amide hydrolase (FAAH) inhibitor URB597 (0.3 mg/kg; Alexis, USA) and then injected immediately after with the same volume of VHL without drug. The animals in the AM group (*n* = 10) were injected i.p. first with the CB₁ receptor inverse agonist AM251 (1 mg/kg; Tocris, UK) and immediately after with the same volume of VHL without drug. In the haloperidol (HAL) group (*n* = 10), animals were injected i.p. first with the DAergic D₂ receptor antagonist haloperidol (0.25 mg/kg; Sigma, Italy) and immediately after with the same volume of VHL without drug. The URB+HAL group (*n* = 10) was injected i.p. with URB597 (0.3 mg/kg) and haloperidol (0.25 mg/kg). The animals in the URB+AM group (*n* = 10) were injected i.p. with URB597 (0.3 mg/kg) and AM251 (1 mg/kg). The control animals (*n* = 10) received the same volume of VHL i.p. twice.

Further, we examined 10 animals that were injected i.p. with AM251 (1 mg/kg) and haloperidol (0.25 mg/kg), but it was not possible to report their results, because they were completely inhibited and remained motionless, failing to seek the reward in either behavioral test.
Drugs were administered at dosages which are reported to have effects on reward-, novelty- and emotion-related behaviors. Namely, the selection of URB597 dosage at 0.3 mg/kg was based on our previous behavioral and electrophysiological results (Rossi et al., 2010; Laricchiuta et al., 2012b, 2013). The same dosage was used by Naderi et al. (2008) to investigate URB597 behavioral effects on anxiety, as well as by Fegley et al. (2005) to characterize its neurochemical profile.

The selection of AM251 dosage at 1 mg/kg was based on behavioral results on locomotor- (Eisenstein et al., 2010), anxiety- (Umathe et al., 2009) and reward- (Xi et al., 2008) related effects. The same dosage was used by Maione et al. (2013) to investigate AM251 neurochemical properties.

The selection of haloperidol dosage at 0.25 mg/kg was based on behavioral results on locomotion and exploration (Karlsson et al., 2008; Chatterjee et al., 2011).

Based on their pharmacokinetic properties (Kathuria et al., 2003; Patel and Hillard, 2006), the drugs were administered 30 min before S3 of the A/A Y-Maze and S1 of the OF task. Two weeks later, the animals were reinjected with the same drugs that they had received and sacrificed 30 min later to take electrophysiological recordings (ER) of the striatal activity. The experimenters that performed the behavioral testing and ER were blind to the drug treatment.

### Statistical Analysis

Data were presented as mean ± SEM and tested for normality (Will-Shapiro’s test) and homoscedasticity (Levene’s test). Behavioral data were compared by ANOVAs, followed by Tukey’s HSD test, when appropriate.

Electrophysiological data were compared by paired or unpaired Student’s t-test.

All analyses were performed using Statistica 7.0 for Windows, and differences were considered significant at \( p \leq 0.05 \).

### Results

#### Behavioral Effects of Drugs Acting on the Endocannabinoid and Dopaminergic Systems

**A/A Y-Maze**

The A/A Y-Maze required animals to choose between two conflicting drives, reaching a palatable reward in an aversive (white and lighted) arm or standard food in a reassuring (black and dark) arm. When white choice frequency was analyzed (Figure 2A) by two-way ANOVA (drug × session), there was significant effects of drug \((F_{(5,54)} = 2.66; p = 0.03)\) and session \((F_{(2,108)} = 147.83; p < 0.00001)\). Also, their interaction was significant \((F_{(10,108)} = 10.22; p < 0.00001)\). Post hoc comparisons on the interaction revealed that the white arm in S1 was chosen least often by the animals of all groups. The frequency of white choices significantly (at least \( p = 0.02 \)) increased in S2.

Between S2 and S3 the VHL group significantly \(( p = 0.006)\) increased their white choice. This response was expected, based on the anxiolytic and familiarization effects with the experimental apparatus with subsequent sessions. The URB group also significantly \(( p = 0.0001)\) chose the white arm more frequently, whereas the AM, URB+AM, and HAL groups did not. Thus, CB1 and DAergic antagonists impeded the increased choice of the white arm.

Notably, in URB+HAL group the coadministration of drugs significantly \(( p = 0.0001)\) increased the frequency of white choices to the same extent as in the URB group. Post hoc comparisons relative to the intergroup differences in S3 are reported in the Figure 2A.

With regard to entry latency (Figure 2B), by two-way ANOVA (drug × session), there were significant drug \((F_{(5,54)} = 6.87; p = 0.00005)\) and session \((F_{(2,108)} = 14.02; p = 0.000004)\) effects. Also, their interaction was significant \((F_{(10,108)} = 15.57; p < 0.00001)\). By post hoc comparisons on interaction, there were no significant differences in latency values between S1 and S2.

In S3, the HAL group had the highest latency values compared with the other groups \(( p = 0.0001)\)—when they stood still, they were in stable equilibrium with a broad-based support and when they were moving, they were slower to initiate (akinesia) and execute movements (bradykinesia). This significant motor slowdown was mitigated in part by the coadministration of URB597 and haloperidol. The URB+HAL group had significantly \(( p = 0.0001)\) lower latency values than the HAL group, higher values than the URB \(( p = 0.002)\) and VHL \(( p = 0.005)\) groups, and similar values as the AM and URB+AM groups. Post hoc comparisons are reported in the Figure 2B.

With regard to defecation boluses, two-way ANOVA (drug × session) indicated no significant drug \((F_{(5,54)} = 2.45; p = 0.06)\) and session \((F_{(2,108)} = 1.25; p = 0.29)\) effect. Also, their interaction was not significant \((F_{(10,108)} = 1.46; p = 0.16)\).

**OF**

The animals were tested in an OF, in which the conflicting situation is represented by inserting an appealing new object in the anxiogenic central location of a wide arena. Two-way ANOVA (drug × session) on total distance traveled in the absence (S1) and presence (S2) of the object revealed a significant effect of drug \((F_{(5,54)} = 108.52; p < 0.00001)\) but not session \((F_{(1,54)} = 1.86; p = 0.17)\). Their interaction was not significant \((F_{(5,54)} = 1.42; p = 0.23)\). Post hoc comparisons on the drug effect indicated that the haloperidol-dependent motor slowdown in the A/A Y-Maze was present also in the OF task. Notably, this effect was not relieved by the coadministration of URB597 and haloperidol–HAL and URB+HAL groups had similar distance values \(( p = 0.90)\). Both groups differed significantly from the remaining groups \(( p = 0.0001)\). Conversely, the AM, URB, URB+AM, and VHL groups traveled similar distances (Figure 3A).

A similar pattern emerged with regard to mean velocity. Two-way ANOVA (drug × session) showed that drug had a significant effect \((F_{(5,54)} = 81.16; p < 0.00001)\) but session did not \((F_{(1,54)} = 3.19; p = 0.08)\); their interaction was not significant \((F_{(5,54)} = 0.97; p = 0.44)\). Post hoc comparisons on the drug effect remarked the haloperidol-dependent motor slowdown, which was not alleviated by URB597 plus haloperidol; the HAL and URB+HAL groups had similar velocity values \(( p = 0.95)\). Both groups differed significantly from the remaining groups \(( p = 0.0001)\); the AM, URB, URB+AM, and VHL groups had similar velocities (Figure 3B).
FIGURE 2 | Behavioral effects of A/A Y-Maze. (A) Between S1 and S2, all animals displayed a significant (at least *p* = 0.02, *) increase in white choices. Between S2 and S3, the VHL (*p* = 0.006, **), URB (*p* = 0.0001, ***), and URB+HAL (*p* = 0.0001, ***), groups increased their white choices, while the AM, URB+AM, and HAL groups did not. The significant post hoc comparisons of the intergroup differences in S3 were: URB (or URB+HAL) vs. AM or HAL or URB+AM: *p* = 0.0002, ###; VHL vs. all the other groups: at least *p* = 0.05, $. (B) Between S1 and S2, no significant differences in entry latency were found. Between S2 and S3, the HAL group had higher latency values (*p* < 0.0001, *****). In S3, the HAL group showed highest entry latency values (vs. URB, URB+HAL, AM, URB+AM groups at least *p* = 0.0001, +++; vs. VHL group *p* = 0.0001, $$$. The haloperidol powerful effect was contrasted but not prevented by URB597 and haloperidol coadministration, as the URB+HAL group had higher latency values than the URB (*p* = 0.002, ##) and VHL (*p* = 0.005, $) groups.

Two-way ANOVA (drug × session) on peripheral distance revealed significant drug (*F*(5,54) = 4.10; *p* = 0.003) and session (*F*(1,54) = 152.80; *p* < 0.00001) effects. Also, their interaction was significant (*F*(5,54) = 2.80; *p* = 0.02). Post hoc comparison on the interaction showed that all groups significantly (at least *p* = 0.05) reduced peripheral distance, from 70% in S1 to 40% of total distance in S2. This significant exploration of the central sectors in the arena during S2 was related to the presence of...
FIGURE 3 | Behavioral effects of OF task. (A) Total distance, (B) velocity, (C) freezing times and (D) contact times in the absence (S1) and presence (S2) of the object. Note the haloperidol-dependent motor inhibition that was not contrasted (or only partially with regard to freezing times) by URB597 and haloperidol coadministration. In S1 and S2, the HAL group had the highest freezing times (vs. URB, URB+HAL, AM, URB+AM groups at least $p = 0.01$, +; vs. VHL group $p = 0.001$, $S$). The URB+HAL group had freezing times higher than URB, AM, URB+AM ($p = 0.001$, ##) and VHL ($p = 0.001$, $$) groups. In (D), the URB group displayed the highest contact times (vs. URB+HAL, URB+AM, HAL, AM groups at least $p = 0.01$, #; vs. VHL group $p = 0.05$, $*$). All groups exhibited contact times significantly (at least $p = 0.04$, $*$) lower than the VHL group.

Two-way ANOVA (drug $\times$ session) on freezing times indicated that the effects of drug ($F_{(5,54)} = 83.48; p < 0.00001$), session ($F_{(1,54)} = 3.79; p = 0.05$), and their interaction were significant ($F_{(5,54)} = 2.77; p = 0.02$). Post hoc comparisons on interaction also showed the significant haloperidol-dependent motor inhibition. The HAL group had the highest freezing times in S1 (at least $p = 0.01$) and S2 (all $p = 0.0001$), an effect that was partially mitigated by the coadministration of URB597 and haloperidol. In S1 and S2, the URB+HAL group had significantly lower freezing times than the HAL group, although significantly (all $p = 0.0001$) higher than the other groups (Figure 3C).

For defecation boluses, two-way ANOVA (drug $\times$ session) revealed no significant drug ($F_{(5,54)} = 2.03; p = 0.08$) or session ($F_{(1,54)} = 1.35; p = 0.31$) effect. Their interaction was not significant ($F_{(5,54)} = 1.96; p = 0.46$).

One-way ANOVA on contact times revealed a significant drug effect ($F_{(5,54)} = 15.62; p < 0.00001$). Post hoc comparisons showed that the URB group had the highest contact times compared with all groups (at least $p = 0.05$). This effect was negated by the action of CB$_1$ inverse agonist, AM251. The AM and URB+AM groups had similar contact times, which were significantly (at least $p = 0.01$) lower than in the VHL group. Also, the HAL and URB+HAL groups had similar contact times that were significantly ($p = 0.04$) lower than in the VHL group (Figure 3D). Thus, the decreased activity of CB$_1$ receptors by AM251 (alone or with URB597) or of D$_2$ receptors by haloperidol (alone or with URB597) inhibited the response to novelty.

ELECTROPHYSIOLOGICAL EFFECTS OF DRUGS ACTING ON THE ENDOCANNABINOID AND DOPAMINERGIC SYSTEMS

Stimulation of CB$_1$ receptors by HU210 significantly inhibited striatal GABAergic sIPSCs in the VHL group ($n = 9$, $p < 0.01$). In vivo treatment with AM251 failed to alter per se sIPSC frequencies ($n = 12$, $p > 0.05$ compared with the VHL group before HU210) (data not shown) but suppressed the effects of HU210 ($n = 10$, $p > 0.05$). This effect was also present in the URB+AM group ($n = 11$, $p > 0.05$). Haloperidol blocked the effects of HU210 on striatal GABAergic synapses ($n = 6$, $p > 0.05$). Notably, CB$_1$ receptor sensitivity was rescued by coadministration of haloperidol and URB597 ($n = 8$, $p < 0.05$), although URB597 alone did not
increase per se the HU210 effects on sIPSCs ($n = 6$, $p < 0.01$ compared with the pre-HU210 value and p n.s. compared with effect of HU210 in the VHL group) (Figure 4).

**DISCUSSION**

In the behavioral tests that we administered, there was a conflict between positive and negative drives; thus, approach and avoidance behaviors were evoked simultaneously. Typically, when these trends have similar strength, the subject remains suspended or, at best, tends to gravitate toward the heavier pole of the conflicting situation. When the subject is re-exposed to the same conflicting situation, the anxiogenic components tend to fade, and the more appealing pole of the conflicting situation is reached more easily. These reasons are why the control animals (VHL group) moved slightly toward the appetitive (palatable food or new object) pole and increased the responses to reward when re-exposed to the task in the A/A Y-Maze.

The main finding of this study was that CB$_1$-mediated processes and their interaction with D$_2$ergic transmission modulated the salience of reward. In S3 of the A/A Y-Maze and in the OF task, animals that were treated with URB597, a drug that potentiates endocannabinoid activity through anandamide increase, had a robust approach behavior toward palatable food and the new object. Notably, AM251, a CB$_1$ inverse agonist, alone and in combination with URB597, blocked the approach behavior, demonstrating that the effect of URB597 on such behavior is mediated by CB$_1$ receptors. Recently, the orphan G-Protein coupled Receptor, GPR55, has been presented as a candidate of cannabinoid receptor subtypes (Ryberg et al., 2007; Lauckner et al., 2008). The GPR55 recognizes cannabinoids, but it differs from CB$_1$ receptor. Some cannabinoids have high affinity for the GPR55 receptor and in low doses can play as an agonist for this receptor. Also the AM251 behaves as an agonist with high affinity for GPR55 receptor (Ryberg et al., 2007). Therefore, in the present study the blockade of the approach behavior observed in the presence of AM251 administration could be related also to the activity of the GPR55 receptors.

CB$_1$ are expressed in several reward-related brain areas, such as the substantia nigra, ventral tegmental area, dorsal and ventral striatum, prefrontal cortex, and corticolimbic structures that receive collateral DAergic innervations (Marsicano and Lutz, 1999; Hermann et al., 2002). Specifically, in the dorsal striatum, CB$_1$ expression is significant in medium spiny neurons that receive DAergic inputs and express D$_1$ and D$_2$ receptors (Monory et al., 2007). Striatal DA efflux rises when anandamide levels are upregulated by URB597 (Solinas et al., 2006). However, in striatal slice preparations, CB$_1$ receptor activation has no effect on DA release (Köfalvi et al., 2005), suggesting that CB$_1$ regulation of DA release involves a multisynaptic mechanism (Riegel and Lupica, 2004; Marinelli et al., 2007).

The administration of haloperidol (D$_2$ antagonist) blocked approach behavior, like AM251 did. However, whereas AM251 did not influence motor function, haloperidol impaired locomotor activity. Consistent with this observation, much evidence indicates that this neuroleptic drug causes dose-dependent akinesia and muscle rigidity (De Ryck et al., 1980; Lorenc-Koci et al., 1996; Ozer et al., 1997).

Coadministration of URB597 and haloperidol counteracted the effects of haloperidol on approach behavior and motor activity. Notably, the effect of ECS potentiation, combined with D$_2$ receptor blockade, developed only when the reward was represented by palatable food. Such a facilitatory effect on food reinforcement appeared to be due to the higher salience of palatable food, based on the hedonic properties of its palatability, compared with the lower salience of the object, regardless of its novelty. The regulation of DAergic processes by the striatal ECS is central to the hedonic aspects of food-seeking (Duarte et al., 2004), food novelty (Bassareo et al., 2002), and need state with regard to hunger (De Luca et al., 2012). CB$_1$ antagonists decrease and CB$_1$ agonists increase DA release that is induced by rewarding stimuli (Cohen et al., 2002; Fadda et al., 2006; Solinas et al., 2006).

In this study, the combination of URB597 and haloperidol affected motor activity. Although slackened, URB+HAL-treated animals had lower entry latencies in the A/A Y-Maze but remained inhibited in the OF task, as evidenced by their total distance and velocity values. Such dissociation between behaviors in the tasks suggests that the reduction in entry latency values in the A/A Y-Maze was a food-dependent effect. The motor slowdown that was evoked by the D$_2$ antagonist was mitigated in the URB+HAL group only when stimulus salience was high, as for palatable food. Likely, the haloperidol increases the amount of glutamate that is released from corticostriatal neurons by counteracting the DA-dependent inhibition of this release, which in turn stimulates striatopallidal output neurons and renders the animal akinetic with muscle rigidity (Yoshida et al., 1994).

It has been suggested that NMDA antagonists alleviate motor slowdown by suppressing the excessive cortical stimulation of the striatopallidal pathway at the level of the striatum (Kaur et al., 1997). Thus, in the URB+HAL group, the partial motor recovery might be linked to the ability of URB597 to potentiate endocannabinoid tone, which in turn activates CB$_1$ receptors that presynaptically inhibit striatal glutamatergic neurotransmission.
This proposal is supported by Giuffrida et al. (1999), who demonstrated that motor activity increases anandamide dorsal striatal release after administration of a Δ1 agonist, a response that is prevented by a Δ2 antagonist. Further, Δ1 agonists did not change the basal outflow of anandamide, underscoring the differences between Δ1 and Δ2 agonists with respect to anandamide release.

Notably, blockade of CB1 activity has opposite effects on psychostimulant-induced hyperactivity (Poncelet et al., 1999). Conversely, inhibitors of the anandamide reuptake or of FAAH attenuate the hyperactivity in hyperdopaminergic mice (Tzavara et al., 2006). Hyperactivity also decreases in response to d-amphetamine treatment in CB1 knockout mice (Tzavara et al., 2009).

Because the behavioral tests of this study integrated an approach-avoidance conflict (reward searching or exploratory drive against brightly lit or open space), the inevitable anxiogenic component that is linked to the conflict must be considered. At least two factors can influence anxiety-like behavior in the A/A Y-Maze and OF tasks: social isolation of the single specimen, resulting from physical separation from cage mates when performing the test, and the aversive feature that is created by the brightly lit, unprotected, novel environment. Thus, both tests can be used to screen for anxiety-related behaviors and analyze the impact of drugs on them.

Drugs that target the ECS elicit anxiolytic or anxiogenic actions. Specifically, in various anxiety paradigms, URB597 has anxiolytic effects (Patel and Hillard, 2006; Moreira et al., 2008; Rubino et al., 2008; Scherma et al., 2008), depending largely on the stress conditions of the experimental protocols, provided that the conditions do not exceed the ECS buffering function (Naidu et al., 2007; Haller et al., 2009). These findings indicate tonic modulation of aversive responses, based on the approach-avoidance conflict. Further, CB1 receptor agonists induce biphasic effects, wherein lower doses are anxiolytic and higher doses are anxiogenic (Viveros et al., 2005). AM251 has an anxiogenic effect when injected at high (3.0 mg/kg) doses and reverses URB597-induced anxiolytic and panicolytic effects (Gobira et al., 2013).

In this study, all groups that were treated with drugs that act on the ECS and DAergic system had similar anxiety levels as the VHL group, based on analysis of primarily anxiety-related parameters—e.g., A/A Y-Maze and OF defecation boluses and OF peripheral distance (thigmotaxis). With regard to OF freezing times, whereas animals that were given ECS-targeted drugs had similar values, the HAL and URB+HAL groups had significantly higher freezing times. However, this increase can not be considered an index of merely enhanced anxiety, because it was heavily influenced by the confounding factor haloperidol-dependent motor slowdown. These findings are consistent with the hypothesis that a fear/anxiety state does not underlie haloperidol-induced catalepsy (Colombo et al., 2013). Similarly, there is no evidence of a relationship between catalepsy and fear/anxiety state in congenic mouse strains (Kondaurova et al., 2011).

Our electrophysiological results complement our behavioral findings. In the VHL and URB groups, stimulation with HU210 (CB1 agonist) inhibited GABAergic dorsal striatal neurotransmission, consistent with previous reports (De Chiara et al., 2010b; Laricchiuta et al., 2012b). In rodents, manipulations with strong reinforcing properties, such as cocaine-induced conditioned place preference, spontaneous running wheel activity, and sucrose consumption, are associated with hypersensitivity of dorsal striatal GABAergic synapses to CB1 stimulation (Centonze et al., 2007a,b; De Chiara et al., 2010b). In a recent study (Laricchiuta et al., 2012b), we reported that enhanced or reduced CB1-mediated control over GABAergic dorsal striatal neurotransmission was associated with spontaneous approach or avoidance behavior toward or away from palatable food, respectively. Further, CB1 activation on GABAergic or glutamatergic neurons has opposite effects on exploratory activity (Häring et al., 2011).

In this study, the administration of the CB1 inverse agonist AM251 (alone or with URB597) or the Δ2 antagonist haloperidol suppressed the effects of HU210 on GABAergic dorsal striatal transmission. These findings are consistent with the observation that Δ2 stimulation activates the dorsal striatal ECS, influencing GABAergic synapses (Centonze et al., 2004, 2007a,b). Notably, in our study, CB1 receptor sensitivity to HU210 was rescued when URB597 and haloperidol were coadministered.

Overall, our behavioral and electrophysiological results demonstrated that by increasing anandamide levels, endocannabinoid potentiation magnified the search for reward and, in parallel, inhibited dorsal striatal GABAergic neurotransmission. Blockade of CB1 or Δ2 receptors inhibited reward-related responses and prevented the inhibition of dorsal striatal GABAergic neurotransmission. Notably, the reward-related response was restored when the blockade of DAergic activity was combined with ECS potentiation. This effect occurred only if the reward was palatable food. Accordingly, the coadministration of URB597 and haloperidol restored the dorsal striatal responses to stimulation with HU210.

Although the use of single doses of drugs might be a limitation in interpreting behavioral and electrophysiological effects we found, it has to be underlined that our results are fully consistent with the hypothesis that endocannabinoids control the reward-related processes and are also implicated in reward-related disorders. Endocannabinoid and DAergic transmission might interact functionally to modulate salient information processing. Abnormalities in the neural mechanisms that govern reward-related processes might underlie the aberrant emotional processing in such disorders as schizophrenia and addiction (Ziauddeen and Murray, 2010; Gardner, 2011). The increase in anandamide in schizophrenic patients might constitute a compensatory response to counteract primary DAergic dysfunction (Giuffrida et al., 2004), advancing the therapeutic potential of the ECS in DA-related disorders. Thus, new insight into ECS activity in reward-related DAergic circuitry should guide the development of pharmacological treatments for eating, drug abuse, and psychiatric disorders.

**Author Contributions**

Daniela Laricchiuta and Diego Centonze designed research; Daniela Laricchiuta, Alessandra Musella and Silvia Rossi performed research; all authors analyzed, discussed and interpreted the data; Daniela Laricchiuta and Diego Centonze wrote the paper and revisited it critically for important intellectual content; all
authors approved the final version of the paper and they agreed to be accountable for all aspects of the work.

ACKNOWLEDGMENTS
The authors would like to thank Professor Laura Petrosini for her help in planning of the experiments and reading the final manuscript. The authors declare that the research was conducted in the absence of any commercial or financial relationships.

REFERENCES
Alcaro, A., and Pankepp, J. (2011). The SEEKING mind: primal neuro-affectove substrates for appetitive incentive states and their pathological dynamics in addictions and depression. *Neurosci. Biobehav. Rev.* 35, 1805–1820. doi: 10.1016/j.neubiorev.2011.03.002

Bassareo, V., De Luca, M. A., and Di Chiara, G. (2002). Differential expression of motivational stimulus properties by dopamine in nucleus accumbens shell versus core and prefrontal cortex. *J. Neurosci.* 22, 4709–4719.

Berke, J. D., and Hyman, S. E. (2000). Addiction, dopamine and the molecular mechanisms of memory. *Neuron* 25, 515–532. doi: 10.1016/S0896-6273(00)01056-9

Centonze, D., Battista, N., Rossi, S., Mercuri, N. B., Finazzi-Agro, A., Bernardi, G., et al. (2004). A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. *Neuropsychopharmacology* 29, 1488–1497. doi: 10.1038/sj.npp.1300458

Centonze, D., Rossi, S., Di Chiara, V., Prosperi, C., Battista, N., Bernardi, G., et al. (2007a). Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. *Eur. J. Neurosci.* 25, 1631–1640. doi: 10.1111/j.1460-9568.2007.05433.x

Centonze, D., Rossi, S., Prosperi, C., Gasperi, V., Di Chiara, V., Bar, M., et al. (2007b). Endocannabinoids limit metabolic glutamate 3 receptor-mediated synaptic inhibition of striatal principal neurons. *Mol. Cell. Neurosci.* 35, 302–310. doi: 10.1016/j.mcn.2007.03.005

Chatterjee, M., Ganguly, S., Srivastava, M., and Palit, G. (2011). Effect of ‘chronic’ versus ‘acute’ ketamine administration and its “withdrawal” effect on behavioural alterations in mice: implications for experimental psychosis. *Behav. Brain Res.* 216, 247–254. doi: 10.1016/j.brainres.2011.03.019

Cohen, C., Perrault, G., Voltz, C., Steinberg, R., and Soubrié, P. (2002). SR 141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and panicolytic activities in the elevated T-maze. *Pharmacol. Biochem. Behav.* 72, 277–285. doi: 10.1016/S0091-3057(01)00509-7

De Chiara, V., Errico, F., Musella, A., Carrara, F., and Bari, M. (2006). Cannabinoid self administration increases dopamine release in the nucleus accumbens. *Neuroreport* 17, 1629–1632. doi: 10.1097/01.wnr.0000216553.40211.8e

Fadda, P., Scherma, M., Sano, M. S., Salis, P., Melis, V., Fattore, L., et al. (2006). Cannabinoid self-administration increases dopamine release in the nucleus accumbens. *Neuroreport* 17, 1629–1632. doi: 10.1097/01.wnr.0000216553.40211.8e

Fattore, L., Sano, M. S., Cossu, G., Deiana, S., and Fratta, W. (2003). Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. *Eur. J. Neurosci.* 17, 1723–1726. doi: 10.1046/j.1460-9568.2003.02607.x

Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzì, G., et al. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3-carboxamido-biphenyl-3-y1 ester (UR89797): effects on anandamide and oleyl ethanolamide deactivation. *J. Pharmacol. Exp. Ther.* 313, 352–358. doi: 10.1124/jpet.104.078980

Fernández-Ruiz, J., Hernández, M., and Ramos, J. A. (2010). Cannabinoid–dopamine interaction in the pathophysiology and treatment of CNS disorders. *CNS Neurosci. Ther.* 16, e72–e91. doi: 10.1111/j.1755-5949.2010.01144.x

Freund, T. F., Katona, I., and Piomelli, D. (2003). Role of endogenous cannabinoids in synaptic signaling. *Physiol. Rev.* 83, 1071–1066.

Gardner, E. L. (2011). Addiction and brain reward and antireward pathways. *Adv. Psychosom. Med.* 30, 22–60. doi: 10.1159/000324805

Giuffrida, A., Di Luzio, F., Schiønning, J. W., Koethe, D., Faulhaber, J., et al. (2004). Cerebropinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. *Neuropsychopharmacology* 29, 2108–2114. doi: 10.1038/sj.npp.1300558

Giuffrida, A., Parsons, L. H., Kerr, T. M., Rodríguez De Fonseca, F., Navarro, M., and Piomelli, D. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. *Nat. Neurosci.* 2, 358–363. doi: 10.1038/9909080898(99)909286-1

Gobira, P. H., Aguilar, D. C., and Moreira, F. A. (2013). Effects of compounds that interfere with the endocannabinoid system on behaviors predictive of anxiolytic and panicolytic activities in the elevated T-maze. *Pharmacol. Biochem. Behav.* 110, 33–39. doi: 10.1016/j.pbb.2013.05.013

Haller, J., Barna, I., Barsvari, B., Gyimesi Pelcz, K., Yasar, S., Paniliov, L. V., et al. (2009). Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. *Psychopharmacology (Berl)* 204, 607–616. doi: 10.1007/s00213-009-1944-7

Haring, M., Kaiser, N., Monory, K., and Lutz, B. (2011). Circuit specific functions of cannabinoid CB1 receptor in the balance of investigatory drive and exploration. *PLoS One* 6:e26617. doi: 10.1371/journal.pone.0026617

Hermann, H., Marsiano, G., and Lutz, B. (2002). Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. *Neuroscience* 109, 451–460. doi: 10.1016/s0306-4522(01)00509-7

Ito, R., Dalley, J. W., Tsvielev, T., and Everitt, B. J. (2002). Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue. *J. Neurosci.* 22, 6247–6253.

Kano, M., Ohno-Shosaku, T., Hashimoto, Y., Uchida, M., and Watanabe, M. (2009). Endocannabinoid-mediated control of synaptic transmission. *Physiol. Rev.* 89, 309–380. doi: 10.1152/physrev.00019.2008

Karlsson, R. M., Tanaka, K., Heilig, M., and Holmes, A. (2008). Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabolic glutamate 2/3 agonist. *Biol. Psychiatry* 64, 810–814. doi: 10.1016/j.biopsych.2008.05.001

Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. *Nat. Med.* 9, 76–81. doi: 10.1038/nm0803

Laricchiuta et al. 2014
Laricchiuta, D., Rojo, M. L., Rodriguez-Gaztelumendi, A., Ferlazzo, F., Petrosini, L., (2013). Effects of endocannabinoid and endovanilloid systems on aversive memory extinction. Behav. Brain Res. 256, 101–107. doi: 10.1016/j.bbr.2013.08.010

Laricchiuta, D., Rojo, M. L., Rodriguez-Gaztelumendi, A., Ferlazzo, F., Petrosini, L., and Fowler, C. J. (2012a). CB1 receptor autoradiographic characterization of the individual differences in approach and avoidance motivation. PLoS One 7:e32360. doi: 10.1371/journal.pone.0032360

Lauckner, J. E., Jensen, J. B., Chen, H. Y., Lu, H. C., Hille, B., and Mackie, K. (2008). GRPR5 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA 105, 2699–2704. doi: 10.1073/pnas.0711278105

Lorenc-Koci, E., Wolfarth, S., and Osovskia, K. (1996). Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp. Brain Res. 109, 268–276. doi: 10.1007/s002210510-7

Lupica, C. R., and Riegel, A. C. (2005). Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacol. 48, 1105–1116. doi: 10.1016/j.neuropharm.2005.03.016

Maccarrone, M., Gubellini, P., Bari, M., Picconi, B., Battista, N., Centonze, D., et al. (2003). Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 85, 1018–1025. doi: 10.1111/j.1471-4159.2003.01759.x

Manoie, S. Costa, B., Pucetelli, F., Moreira, E., De Chiara, M., Comelli, F., et al. (2013). Piperazine carbatate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics. Pharmacol. 76, 98–105. doi: 10.1016/j.phrs.2013.07.003

Maldonado, R., and Rodriguez de Fonseca, F. (2002). Cannabinoid addiction: behavioral models and neural correlates. J. Neurosci. 22, 3326–3331.

Maldonado, R., Valverde, O., and Berrendero, F. (2006). Involvement of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacol. 54, 141–150. doi: 10.1016/j.neuropharm.2007.07.005

Mesula, A., Sepman, H., Mandolesi, G., Gentile, A., Fresnega, D., Haji, N., et al. (2014). Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis. Neuropharmacol. 79, 567–572. doi: 10.1016/j.neuropharm.2014.01.007

Naderi, N., Haghighat, A., Saber-Tehrani, A., Razaei, N., Alizadeh, A. M., Khani, A., et al. (2008). Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol. Biochem. Behav. 89, 64–75. doi: 10.1016/j.pbb.2007.11.001

Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., and Lichtman, A. H. (2007). Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Beri) 192, 61–70. doi: 10.1007/s00213-006-0689-4

Ozer, H., Ekinci, A. C., and Starr, M. S. (1997). Dopamine D1- and D2-dependent catalepsy in the rat requires functional NMDA receptors in the corpus striatum, nucleus accumbens and substantia nigra pars reticulata. Brain Res. 777, 51–59. doi: 10.1016/S0006-8993(97)00706-3

Patel, S., and Hillard, C. J. (2006). Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther. 318, 304–311. doi: 10.1124/jpet.105.082977

Piomelli, D. (2003). The molecular logic of endocannabinoid signaling. Nat. Rev. Neurosci. 4, 873–884. doi: 10.1038/nrn1247

Poncelet, M., Barnouin, M. C., Brelire, J. C., Le Fur, G., and Soubré, P. (1999). Blockade of cannabinoid (CB1) receptors by 141IT16 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Beri) 144, 144–150. doi: 10.1007/s002130500987

Riegel, A. C., and Lupica, C. R. (2004). Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J. Neurosci. 24, 11070–11078. doi: 10.1523/jneurosci.2693-04.2004

Rossi, S., De Chiara, V., Musella, A., Sacchetti, L., Cantarella, C., Castelli, M., et al. (2010). Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition. Mol. Pharmacol. 78, 260–268. doi: 10.1124/mol.110.064196

Rubino, T., Guida1, C., Viganò, D., Realini, N., Valenti, M., Massi, P., et al. (2008). CB1 receptor stimulation in specific brain areas differentially modulates anxiety-related behaviour. Neuropharmacol. 54, 151–160. doi: 10.1016/j.neuropharm.2007.06.024

Ryberg, E., Larsson, N., Siogren, S., Hjorth, S., Hermansson, N. O., Leonova, J., et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1902–1911. doi: 10.1111/j.1476-5381.2007.057066.x

Scherna, M., Medalie, J., Fratta, W., Vadivel, S. K., Makriyannis, A., Piomelli, D., et al. (2008). The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase inhibition. Neuropharmacol. 54, 129–140. doi: 10.1016/j.neuropharm.2007.08.011

Solinus, M., Justinova, Z., Goldberg, S. R., and Tanda, G. (2006). Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J. Neurochem. 98, 408–419. doi: 10.1111/j.1471-4159.2006.08380.x

Tzavara, E. T., Li, D. L., Moutsimilli, L., Bisogno, T., Di Marzo, V., Phebus, L. A., et al. (2006). Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Eur. Neuropsychopharmacol. 16, 19–204. doi: 10.1016/j.euroneuro.2008.11.003

Tzavara, E. T., Li, D. L., Moutsimilli, L., Bisogno, T., Di Marzo, V., Phebus, L. A., et al. (2006). Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry 59, 508–515. doi: 10.1016/j.biopsych.2005.08.019

Ushioe, N., Manna, S. S., Utturwar, K. S., and Jain, N. S. (2009). Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors. Prog. Neuropharmacol. Biol. Psychiatry 33, 1191–1199. doi: 10.1016/j.pnpbp.2009.06.020

Van Laere, K., Goffin, K., Bormans, G., Casteels, C., Mortelmans, L., and Hoon, J., et al. (2009). Relationship of type 1 cannabinoid receptor availability in the human brain to novelty-seeking temperament. Arch. Gen. Psychiatry 66, 196–204. doi: 10.1001/archgenpsychiatry.2008.530
Viveros, M. P., Marco, E. M., and File, S. E. (2005). Endocannabinoid system and stress and anxiety responses. *Pharmacol. Biochem. Behav.* 81, 331–342. doi: 10.1016/j.pbb.2005.01.029

Xi, Z. X., Spiller, K., Pak, A. C., Gilbert, J., Dillon, C., Li, X., et al. (2008). Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. *Neuropsychopharmacology* 33, 1735–1745. doi: 10.1038/sj.npp.1301552

Yoshida, Y., Ono, T., Kawano, K., and Miyagishi, T. (1994). Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen. *Brain Res.* 639, 139–148. doi: 10.1016/0006-8993(94)91774-4

Ziauddeen, H., and Murray, G. K. (2010). The relevance of reward pathways for schizophrenia. *Curr. Opin. Psychiatry* 23, 91–96. doi: 10.1097/yco.0b013e328336661b

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 04 February 2014; accepted: 04 May 2014; published online: 19 May 2014.

Citation: Laricchiuta D, Musella A, Rossi S and Centonze D (2014) Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli. *Front. Behav. Neurosci.* 8:183. doi: 10.3389/fnbeh.2014.00183

This article was submitted to the journal *Frontiers in Behavioral Neuroscience*. Copyright © 2014 Laricchiuta, Musella, Rossi and Centonze. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.